The quest for modernisation of traditional Chinese medicine

BMC Complementary and Alternative Medicine

Peter J Hylands²  De-an Guo⁸  Nicola Robinson³  Aiping Lu⁴  Claudia M Witt¹  Monique SJ Simmonds⁶  Pierre Duez⁹  Zhongzhen Zhao⁴  Tai-Ping Fan⁵  Bruce M Hendry^1,10  Rudolf Bauer⁷  Qihe Xu^1,10 

[1]Institute for Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin, Berlin, Germany

[2]King's College London, Institute of Pharmaceutical Science, London, UK

[3]Allied Health Sciences, Faculty of Health and Social Care, London South Bank University, London, UK

[4]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China

[5]Department of Pharmacology, University of Cambridge, Cambridge, UK

[6]Royal Botanic Gardens, Kew, Richmond, Surrey, UK

[7]Institute of Pharmaceutical Sciences, Department of Pharmacognosy, Karl-Franzens-University Graz, Graz, Austria

[8]Shanghai Research Centre for TCM Modernisation, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

[9]Laboratory of Pharmacognosy, Bromatology and Human Nutrition, Université Libre de Bruxelles, Brussels, Belgium

[10]King's College London, Department of Renal Medicine, London, UK

关键词: Innovation;    Integration;    Integrity;    Safety;    Efficacy;    Science;    History;    Acupuncture;    Chinese herbal medicine;    Evidence-based medicine;   

Others  :  1229852
DOI  :  10.1186/1472-6882-13-132

 received in 2013-02-17, accepted in 2013-05-28,  发布年份 2013

【 摘 要 】

Traditional Chinese medicine (TCM) is an integral part of mainstream medicine in China. Due to its worldwide use, potential impact on healthcare and opportunities for new drug development, TCM is also of great international interest. Recently, a new era for modernisation of TCM was launched with the successful completion of the Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era (GP-TCM) project, the European Union’s Seventh Framework Programme (FP7) coordination action on TCM research. This 3.5-year project that involved inputs from over 200 scientists resulted in the production of 20 editorials and in-depth reviews on different aspects of TCM that were published in a special issue of Journal of Ethnopharmacology (2012; volume 140, issue 3). In this narrative review, we aim to summarise the findings of the FP7 GP-TCM project and highlight the relevance of TCM to modern medicine within a historical and international context. Advances in TCM research since the 1950s can be characterised into three phases: Phase I (1950s-1970s) was fundamental for developing TCM higher education, research and hospital networks in China; Phase II (1980s-2000s) was critical for developing legal, economic and scientific foundations and international networks for TCM; and Phase III (2011 onwards) is concentrating on consolidating the scientific basis and clinical practice of TCM through interdisciplinary, interregional and intersectoral collaborations. Taking into account the quality and safety requirements newly imposed by a globalised market, we especially highlight the scientific evidence behind TCM, update the most important milestones and pitfalls, and propose integrity, integration and innovation as key principles for further modernisation of TCM. These principles will serve as foundations for further research and development of TCM, and for its future integration into tomorrow’s medicine.

【 授权许可】

   
2013 Xu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Cai J: Integration of traditional Chinese medicine with Western medicine – Right or wrong. Soc Sci Med 1988, 27:521-529.
• [2]Fazel M: Now show me your tongue: a taste of medicine in China. Lancet 1995, 346:1687-1688.
• [3]Scheid V: The globalization of Chinese medicine. Lancet 1999, 354:SIV10.
• [4]Tang JL, Liu BY, Ma KW: Traditional Chinese medicine. Lancet 2008, 372:1938-1940.
• [5]Unschuld PU: The past 1000 years of Chinese medicine. Lancet 1999, 354:SIV9.
• [6]Qiu J: China plans to modernize traditional medicine. Nature 2007, 446:590-591.
• [7]Wright P: Passport to Peking: A very British mission to Mao's China. Oxford: Oxford University Press; 2010.
• [8]James DW: Chinese medicine. Lancet 1955, 265:1068-1069.
• [9]Porkert M: Klinische chinesische Pharmakologie. Heidelberg: Verlag für Medizin Fischer; 1978.
• [10]Harmsworth K, Lewith GT: Attitudes to traditional Chinese medicine amongst Western trained doctors in the People's Republic of China. Soc Sci Med 2001, 52:149-153.
• [11]Gaw AC, Chang LW, Shaw L-C: Efficacy of acupuncture on osteoarthritic pain. A controlled, double-blind study. N Engl J Med 1975, 293:375-378.
• [12]Pomeranz B, Chiu D: Naloxone blockade of acupuncture analgesia: endorphin implicated. Life Sci 1976, 19:1757-1762.
• [13]Mayer DJ, Price DD, Rafii A: Antagonism of acupuncture analgesia in man by the narcotic antagonist naloxone. Brain Res 1977, 121:368-372.
• [14]Han JS: Acupuncture and endorphins. Neurosci Lett 2004, 361:258-261.
• [15]Tu Y: The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 2011, 17:1217-1220.
• [16]Miller LH, Su X: Artemisinin: discovery from the Chinese herbal garden. Cell 2011, 146:855-858.
• [17]Neill US: From branch to bedside: Youyou Tu is awarded the 2011 Lasker~DeBakey Clinical Medical Research Award for discovering artemisinin as a treatment for malaria. J Clin Invest 2011, 121:3768-3773.
• [18]Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966, 88:3888-3890.
• [19]Wall M, Wani M: Camptothecin: Discovery to Clinic. Ann N Y Acad Sci 1996, 803:1-12.
• [20]Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
• [21]Wall ME, Wani MC: Camptothecin and taxol: discovery to clinic - Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995, 55:753-760.
• [22]Melchart D, Linde K, Weidenhammer W, Hager S, Liao J, Bauer R, Wagner H: Use of traditional drugs in a hospital of Chinese medicine in Germany. Pharmacoepidemiol Drug Saf 1999, 8:115-120.
• [23]Wang S: On the modalities of modern traditional Chinese medicine education. Journal of Shanxi College of Traditional Chinese Medicine 2012, 3:69-71.
• [24]Pearson NJ, Chesney MA: The National Center for Complementary and Alternative Medicine. Acad Med 2007, 82:967.
• [25]The Australian National Institute of Complementary Medicine website. http://www.nicm.edu.au/about-nicm webcite
• [26]Medicine and Health: The Eurasia-Pacific Uninet webpage. http://www.eurasiapacific.net/index.php?page=content&pid=18 webcite
• [27]Uzuner H, Fan TP, Dias A, Guo DA, El-Nezami HS, Xu Q: Establishing an EU-China consortium on traditional Chinese medicine research. Chin Med 2010, 5:42. BioMed Central Full Text
• [28]World Health Organization webpage for the article Medicinal Plants in China: A Selection of 150 Commonly Used Species. http://whqlibdoc.who.int/wpro/-1993/9290611022.pdf webcite
• [29]Burr W: WHO moves to classify traditional medicines. CMAJ 2011, 183:E73-E74.
• [30]ISO webpage for its TCM Technical Committee. http://www.iso.org/iso/standards_development/technical_committees/other_bodies/iso_technical_committee.htm?commid=598435 webcite
• [31]UNESCO web page on acupuncture and moxibustion. http://www.unesco.org/culture/ich/en/RL/00425 webcite
• [32]UNESCO web page on Ben Cao Gang Mu (Compendium of Materia Medica). http://www.unesco.org/new/en/communication-and-information/flagship-project-activities/memory-of-the-world/register/full-list-of-registered-heritage/registered-heritage-page-1/ben-cao-gang-mu-compendium-of-materia-medica/ webcite
• [33]UNESCO web page on Huang Di Nei Jing (Yellow Emperor's Inner Canon). http://www.unesco.org/new/en/communication-and-information/flagship-project-activities/memory-of-the-world/register/full-list-of-registered-heritage/registered-heritage-page-4/huang-di-nei-jing-yellow-emperors-inner-canon/ webcite
• [34]Skrabanek P: Acupuncture and the age of unreason. Lancet 1984, 323:1169-1171.
• [35]Streitberger K, Kleinhenz J: Introducing a placebo needle into acupuncture research. Lancet 1998, 352:364-365.
• [36]Witt C, Brinkhaus B, Jena S, Linde K, Streng A, Wagenpfeil S, Hummelsberger J, Walther HU, Melchart D, Willich SN: Acupuncture in patients with osteoarthritis of the knee: a randomised trial. Lancet 2005, 366:136-143.
• [37]Cheng TO: Medicine in China. Lancet 1996, 347:774.
• [38]Fugh-Berman A: Herb-drug interactions. Lancet 2000, 355:134-138.
• [39]Fushimi R, Tachi J, Amino N, Miyai K: Chinese medicine interfering with digoxin immunoassays. Lancet 1989, 333:339.
• [40]Atherton DJ, Sheehan MP, Rustin M: Traditional Chinese plants for eczema. Lancet 1991, 338:510.
• [41]Sheehan MP, Rustin MH, Atherton DJ, Buckley C, Harris DW, Brostoff J, Ostlere L, Dawson A: Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992, 340:13-17.
• [42]Chan TY, Chan JC, Tomlinson B, Critchley JA: Chinese herbal medicines revisited: a Hong Kong perspective. Lancet 1993, 342:1532-1534.
• [43]Jadoul M, de Plaen JF, Cosyns JP, Van Ypersele de Strihou C: Adverse effects from traditional Chinese medicine. Lancet 1993, 341:892-893.
• [44]Tai YT, But PP, Young K, Lau CP: Adverse effects from traditional Chinese medicine. Lancet 1993, 341:892.
• [45]Hanson M: Maoist public-health campaigns, Chinese medicine, and SARS. Lancet 2008, 372:1457-1458.
• [46]Lampert N: Complementary and alternative medicine. Lancet 2001, 357:802.
• [47]Ross C: New life for old medicine. Lancet 1993, 342:485-486.
• [48]Okada F: Kampo medicine, a source of drugs waiting to be exploited. Lancet 1996, 348:5-6.
• [49]Wang J: Evidence-based medicine in China. Lancet 2010, 375:532-533.
• [50]Sheng-Ji P: Ethnobotanical approaches of traditional medicine studies: some experiences from Asia. Pharm Biol 2001, 39(Suppl 1):74-79.
• [51]Xiao PG, et al.: Pictorial of Encyclopaedia of Chinese Herbal Medicine. Volume 1–12. Hong Kong: The Commercial Press; 1988-1997.
• [52]Li D, Xiao P, Liu C: Modern Research and Application of Chinese Medicinal Plants. Hong Kong: Hong Kong Medical Publisher; 2000.
• [53]Xiao PG: Modern Chinese Materia Medica. Volume 1–5. Beijing: Chemical Industry Press; 2002–2007.
• [54]Zhao ZZ, Xiao PG: Encyclopedia of Contemporary Medicinal Plants (English Version). Volume 1–4. Shanghai: World Publishing Corporation; 2010.
• [55]Wagner H, Bauer R, Melchart D, Xiao PG, Staudinger A: Chromatographic Fingerprint Analysis of Herbal Medicines - Thin-layer and High Performance Liquid Chromatography of Chinese Drugs. Volume 1- 2. Vienna: Springer-Verlag; 2011.
• [56]Bauer R, Franz G: Modern European monographs for quality control of Chinese herbs. Planta Med 2010, 76:2004-2011.
• [57]Sheehan MP, Atherton DJ: One-year follow up of children treated with Chinese medicinal herbs for atopic eczema. Br J Dermatol 1994, 130:488-493.
• [58]Batey RG, Bensoussan A, Fan YY, Bollipo S, Hossain MA: Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 1998, 13:244-247.
• [59]Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M: Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998, 280:1585-1589.
• [60]Normile D: The New Face of Traditional Chinese Medicine. Science 2003, 299:188-190.
• [61]Fan TP, Deal G, Koo HL, Rees D, Sun H, Chen S, Dou JH, Makarov VG, Pozharitskaya ON, Shikov AN, Kim YS, Huang YT, Chang YS, Jia W, Dias A, Wong VC, Chan K: Future development of global regulations of Chinese herbal products. J Ethnopharmacol 2012, 140:568-586.
• [62]Jiang M, Yang J, Zhang C, Liu B, Chan K, Cao H, Lu A: Clinical studies with traditional Chinese medicine in the past decade and future research and development. Planta Med 2010, 76:2048-2064.
• [63]Junhua Z, Hongcai S, Xiumei G, Boli Z, Yaozu X, Hongbo C, Ming R: Methodology and reporting quality of systematic review/meta-analysis of traditional Chinese medicine. J Altern Complement Med 2007, 13:797-805.
• [64]He Y, Lu A, Zha Y, Yan X, Song Y, Zeng S, Liu W, Zhu W, Su L, Feng X, Qian X, Lu C: Correlations between symptoms as assessed in traditional chinese medicine (TCM) and ACR20 efficacy response: a comparison study in 396 patients with rheumatoid arthritis treated with TCM or Western medicine. J Clin Rheumatol 2007, 13:317-321.
• [65]Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, Gu L, Dong JP, Liang LR, Li XW, Hu K, He XS, Sun YH, An Y, Yang T, Cao ZX, Guo YM, Wen XM, Wang YG, Liu YL, Jiang LD: Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med 2011, 155:217-225.
• [66]Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, Lewith G: Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol 2012, 140:550-554.
• [67]Chan K, Shaw D, Simmonds MS, Leon CJ, Xu Q, Lu A, Sutherland I, Ignatova S, Zhu YP, Verpoorte R, Williamson EM, Duez P: Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese materia medica. J Ethnopharmacol 2012, 140:469-475.
• [68]Ouedraogo M, Baudoux T, Stévigny C, Nortier J, Colet JM, Efferth T, Qu F, Zhou J, Chan K, Shaw D, Pelkonen O, Duez P: Review of current and “omics” methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines. J Ethnopharmacol 2012, 140:492-512.
• [69]De Broe ME: Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney Int 2012, 81:513-515.
• [70]Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP: Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA 2012, 109:8241-8246.
• [71]The booklet Towards a Safer Choice- The Practice of Chinese Medicine In Australia by Bensoussan A & Myers SP on the website of Department of Human Services, Victoria, Australia. http://www.health.vic.gov.au/archive/archive2006/chinese/report/contents.html webcite
• [72]Fu PP, Xia QS, Lin G, Chou MW: Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 2004, 36:1-55.
• [73]Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C: Pharmacovigilance of herbal medicine. J Ethnopharmacol 2012, 140:513-518.
• [74]Zhang L, Yan J, Liu X, Ye Z, Yang X, Meyboom R, Chan K, Shaw D, Duez P: Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: current status and future perspective. J Ethnopharmacol 2012, 140:519-525.
• [75]Chen ST, Dou J, Temple R, Agarwal R, Wu KM, Walker S: New therapies from old medicines. Nat Biotechnol 2008, 26:1077-1083.
• [76]Vlietinck A, Pieters L, Apers S: Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European Union. Planta Med 2009, 75:683-688.
• [77]Dobos GJ, Tan L, Cohen MH, McIntyre M, Bauer R, Li X, Bensoussan A: Are national quality standards for traditional Chinese herbal medicine sufficient? Current governmental regulations for traditional Chinese herbal medicine in certain Western countries and China as the Eastern origin country. Compl Ther Med 2005, 13:183-190.
• [78]Zhang B, Peng Y, Zhang Z, Liu H, Qi Y, Liu S, Xiao P: GAP production of TCM herbs in China. Planta Med 2010, 76:1948-1955.
• [79]Heuberger H, Bauer R, Friedl F, Heubl G, Hummelsberger J, Nögel R, Seidenberger R, Torres-Londoño P: Cultivation and breeding of Chinese medicinal plants in Germany. Planta Med 2010, 76:1956-1962.
• [80]Zhao Z, Guo P, Brand E: The formation of daodi medicinal materials. J Ethnopharmacol 2012, 140:476-481.
• [81]Pferschy-Wenzig E-M, Bauer R: Quality control of Chinese herbal drugs. In Evaluation of herbal medicinal products: perspectives on quality, safety, and efficacy. Edited by Houghton P, Mukherjee PK. London: Pharmaceutical Press; 2009:1-502.
• [82]Heubl G: New aspects of DNA-based authentication of Chinese medicinal plants by molecular biological techniques. Planta Med 2010, 76:1963-1974.
• [83]Liang YZ, Xie PS, Chan K: Perspective of chemical fingerprinting of Chinese herbs. Planta Med 2010, 76:1997-2003.
• [84]Sheridan H, Krenn L, Jiang R, Sutherland I, Ignatova S, Marmann A, Liang X, Sendker J: The potential of metabolic fingerprinting as a tool for the modernisation of TCM preparations. J Ethnopharmacol 2012, 140:482-491.
• [85]Tilton R, Paiva AA, Guan JQ, Marathe R, Jiang Z, van Eyndhoven W, Bjoraker J, Prusoff Z, Wang H, Liu SH, Cheng YC: A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906. Chin Med 2010, 5:30. BioMed Central Full Text
• [86]Tejedor Garcia N, Garcia Bermejo L, Fernandez Martinez AB, Olmos Centenera G, Kumari R, Xu Q, Cheng X, Watson S, de Lucio Cazaña FJ: MEDLINE-based assessment of animal studies on Chinese herbal medicine. J Ethnopharmacol 2012, 140:545-549.
• [87]Zhao ZZ, Liang ZT, Chan K, Lu GH, Lee ELM, Chen HB, Li L: A unique issue in the standardization of Chinese Materia Medica: Processing. Planta Med 2010, 76:1975-1986.
• [88]Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K: Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5’-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 2000, 97:1433-1437.
• [89]Junio HA, Sy-Cordero AA, Ettefagh KA, Burns JT, Micko KT, Graf TN, Richter SJ, Cannon RE, Oberlies NH, Cech NB: Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis). J Nat Prod 2011, 74:1621-1629.
• [90]Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, Chen SJ, Chen Z: Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 2008, 105:4826-4831.
• [91]Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, Liu SH, Cheng YC: The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med 2010, 2:45ra59.
• [92]Wang E, Bussom S, Chen J, Quinn C, Bedognetti D, Lam W, Guan F, Jiang Z, Mark Y, Zhao Y, Stroncek DF, White J, Marincola FM, Cheng YC: Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Med Genomics 2011, 4:38. BioMed Central Full Text
• [93]Liu SH, Cheng YC: Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. J Ethnopharmacol 2012, 140:614-623.
• [94]Stone R: Biochemistry. Lifting the veil on traditional Chinese medicine. Science 2008, 319:709-710.
• [95]Zhang X, Liu Y, Guo Z, Feng J, Dong J, Fu Q, Wang C, Xue X, Xiao Y, Liang X: The herbalome - an attempt to globalize Chinese herbal medicine. Anal Bioanal Chem 2012, 402:573-581.
• [96]Norheim AJ: Adverse effects of acupuncture: a study of the literature for the years 1981–1994. J Altern Complement Med 1996, 2:291-297.
• [97]MacPherson H, Thomas K, Walters S, Fitter M: The York acupuncture safety study: prospective survey of 34,000 treatments by traditional acupuncturists. BMJ 2001, 323:486-487.
• [98]White A, Hayhoe S, Hart A, Ernst E: Adverse events following acupuncture: prospective survey of 32,000 consultations with doctors and physiotherapists. BMJ 2001, 323:485-486.
• [99]Melchart D, Weidenhammer W, Streng A, Reitmayr S, Hoppe A, Ernst E, Linde K: Prospective investigation of adverse effects of acupuncture in 97733 patients. Arch Intern Med 2004, 164:104-105.
• [100]Witt CM, Pach D, Brinkhaus B, Wruck K, Tag B, Mank S, Willich SN: Safety of acupuncture: results of a prospective observational study with 229, 230 patients and introduction of a medical information and consent form. Forsch Komplementarmed 2009, 16:91-97.
• [101]Linde K, Witt CM, Streng A, Weidenhammer W, Wagenpfeil S, Brinkhaus B, Willich SN, Melchart D: The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain 2007, 128:264-271.
• [102]Wechsler ME, Kelley JM, Boyd IO, Dutile S, Marigowda G, Kirsch I, Israel E, Kaptchuk TJ: Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 2011, 365:119-126.
• [103]Berman BM, Lao L, Langenberg P, Lee WL, Gilpin AM, Hochberg MC: Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee: a randomized, controlled trial. Ann Intern Med 2004, 141:901-910.
• [104]Haake M, Müller HH, Schade-Brittinger C, Basler HD, Schäfer H, Maier C, Endres HG, Trampisch HJ, Molsberger A: German Acupuncture Trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. Arch Intern Med 2007, 167:1892-1898.
• [105]Linde K, Streng A, Jürgens S, Hoppe A, Brinkhaus B, Witt C, Wagenpfeil S, Pfaffenrath V, Hammes MG, Weidenhammer W, Willich SN, Melchart D: Acupuncture for patients with migraine: a randomized controlled trial. JAMA 2005, 293:2118-2125.
• [106]Vickers AJ, Rees RW, Zollman CE, McCarney R, Smith CM, Ellis N, Fisher P, Van Haselen R: Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial. BMJ 2004, 328:744.
• [107]Witt CM, Jena S, Selim D, Brinkhaus B, Reinhold T, Wruck K, Liecker B, Linde K, Wegscheider K, Willich SN: Pragmatic randomized trial evaluating the clinical and economic effectiveness of acupuncture for chronic low back pain. Am J Epidemiol 2006, 164:487-496.
• [108]Brinkhaus B, Hummelsberger J, Kohnen R, Seufert J, Hempen CH, Leonhardy H, Nögel R, Joos S, Hahn E, Schuppan D: Acupuncture and Chinese herbal medicine in the treatment of patients with seasonal allergic rhinitis: a randomized- controlled clinical trial. Allergy 2004, 59:953-960.
• [109]Vickers AJ, Cronin AM, Maschino AC, Lewith G, Macpherson H, Foster NE, Sherman KJ, Witt CM, Linde K: for the Acupuncture Trialists’ Collaboration: Acupuncture for chronic pain: individual patient meta-analysis. Arch Intern Med 2012, 172:1444-1453.
• [110]Cummings M: Modellvorhaben Akupunktur - a summary of the ART, ARC and GERAC trials. Acupunct Med 2009, 27:26-30.
• [111]Guidance on the management of back pain on the UK National Institute for Health and Clinical Excellence website. http://www.nice.org.uk/nicemedia/live/11887/44343/44343.pdf webcite
• [112]Guidance on the diagnosis and management of headaches on the UK National Institute for Health and Clinical Excellence website. http://www.nice.org.uk/nicemedia/live/13901/60853/60853.pdf webcite
• [113]Burnstock G: Acupuncture: a novel hypothesis for the involvement of purinergic signalling. Med Hypotheses 2009, 73:470-472.
• [114]Goldman N, Chen M, Fujita T, Xu Q, Peng W, Liu W, Jensen TK, Pei Y, Wang F, Han X, Chen JF, Schnermann J, Takano T, Bekar L, Tieu K, Nedergaard M: Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci 2010, 13:883-888.
• [115]Lasker~DeBakey Clinical Medical Research Award 2011 Winners. http://www.laskerfoundation.org/awards/2011_c_description.htm webcite
• [116]National Foundation for Cancer Research Szent-Györgyi Prize. http://www.nfcr.org/asg-prize/prize-winners webcite
• [117]Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine. http://scm.hkbu.edu.hk/en/cm-award/intro/index.html webcite
• [118]Chen K, Zhang Z, Liang Z: Blood stasis and research of activating blood circulation and eliminating stasis. Shanghai: Shanghai Science & Technology Press; 1990.
• [119]Liu Y, Yin HJ, Shi DZ, Chen KJ: Chinese herb and formulas for promoting blood circulation and removing blood stasis and antiplatelet therapies. Evid Based Complement Alternat Med 2012, 201(2):184503.
• [120]Uzuner H, Bauer R, Fan TP, Guo DA, Dias A, El-Nezami H, Efferth T, Williamson EM, Heinrich M, Robinson N, Hylands PJ, Hendry BM, Cheng YC, Xu Q: Traditional Chinese medicine research in the post-genomic era: Good practice, priorities, challenges and opportunities. J Ethnopharmacol 2012, 140:458-468.
• [121]The GP-TCM Research Association website. http://www.gp-tcm.org webcite
• [122]Ehrman TM, Barlow DJ, Hylands PJ: Phytochemical informatics of traditional Chinese medicine and therapeutic relevance. J Chem Inf Model 2007, 47:2316-2334.
• [123]van der Greef J: Perspective: All systems go. Nature 2011, 480:S87.
• [124]Wang C, Schmid CH, Rones R, Kalish R, Yinh J, Goldenberg DL, Lee Y, McAlindon T: A randomized trial of tai chi for fibromyalgia. N Engl J Med 2010, 363:743-754.
• [125]Li F, Harmer P, Fitzgerald K, Eckstrom E, Stock R, Galver J, Maddalozzo G, Batya SS: Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med 2012, 366:511-519.
• [126]van der Greef J, Hankemeier T, McBurney RN: Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics 2006, 7:1087-1094.
• [127]Buriani A, Garcia-Bermejo ML, Bosisio E, Xu Q, Li H, Dong X, Simmonds MS, Carrara M, Tejedor N, Lucio-Cazana J, Hylands PJ: Omic techniques in systems biology approaches to traditional Chinese medicine research: present and future. J Ethnopharmacol 2012, 140:535-544.
• [128]Gallo C: The innovation secrets of Steve Jobs. Columbus: McGraw-Hill Companies, Inc; 2011.